MIGENIX Inc. (MIGENIX) is a biopharmaceutical company engaged in the research, development and commercialization of drugs for the treatment of infectious diseases. The Company's programs include drug candidates for the treatment and prevention of hospital-acquired and other infections, the treatment of dermatological diseases, the treatment of chronic hepatitis C infections and the treatment of hepatitis B infections. As of April 30, 2008, the Company had no products approved for sale. The Company’s operations are located in Canada. During the fiscal year ended April 30, 2009 (fiscal 2009), the Company closed its United States operations.